Evidence map›Paper›PMID 28649557›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2017

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients.

Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Zack Scott, Jenna Elder, Stephen T Sonis and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03237325 (A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03237325 phase3completednot on this map

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

TypeinterventionalSponsorSoligenixRan2017 to 2021Enrolled266ConditionsSquamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral MucositisArmsSGX942, Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Unraveling the complexity of radiotherapy- and chemotherapy-induced oral mucositis: insights into pathogenesis and intervention strategies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Review
  2. Review
  3. The Role of the Innate Immune Response in Oral Mucositis Pathogenesis.International journal of molecular sciences · 2023
    Review
  4. Are Antimicrobial Peptides a 21st-Century Solution for Atopic Dermatitis?International journal of molecular sciences · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Current trends in targeted therapy for drug-resistant infections.Applied microbiology and biotechnology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mahesh KudrimotiRadiation Oncology, University of Kentucky, 800 Rose Street, Lexington, KY, 40536, USA.
Amarinthia CurtisGibbs Cancer Center, Spartanburg Regional Hospital, 101 E Wood, Spartanburg, SC, 29303, USA.
Samar AzawiVeteran's Affairs Long Beach Hospital, 5901 E 7th Street, Mail Code 114A, Long Beach, CA, 98022, USA.
Francis WordenDepartment of Medicine, University of Michigan Health System,1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA.
Sanford KatzDepartment of Radiation Oncology, Willis-Knighton Cancer Center,2600 Kings Highway, Shreveport, LA, 71103, USA.
Douglas AdkinsDivision of Hematology and Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO, 63110, USA.
Marcelo BonomiDepartment of Hematology and Oncology, Wake Forest Health Sciences Medical Center, 1 Medical Center Blvd., Winston-Salem, NC, 27157, USA.
Zack ScottPharPoint Research, 5003 S Miami Blvd #100, Durham, NC, 27703, USA.
Jenna ElderPharPoint Research, 5003 S Miami Blvd #100, Durham, NC, 27703, USA.
Stephen T SonisOral Medicine and Diagnostic Services, Dana Farber/Harvard Cancer Center, Boston, MA, USA.
Richard StraubeSoligenix Inc., 29 Emmons Drive, Suite C-10, Princeton, NJ, 08540, USA.
Oreola DoniniSoligenix Inc., 29 Emmons Drive, Suite C-10, Princeton, NJ, 08540, USA.

Funding

SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck CancerR43DE024032 · NIDCR · SOLIGENIX, INC. · PI STRAUBE, RICHARD CONRAD · 2014 to 2014
$225k
NIDCR NIH HHS R43 DE024032
6 · The paper itself

Abstract

Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.

Indexed as

Cancer supportive careCRT, chemoradiation therapyDusquetideHead and neck cancerHNC, head and neck cancerIDR, innate defense regulatorImmuneInnateOM, oral mucositisOral mucositisSOM, severe oral mucositis

Identifiers

PMID28649557
PMCPMC5470438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.